Drugs / Lonidamine
Lonidamine
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00237536 | Jun 2005 → Aug 2006 | benign prostatic hyperplasia | Threshold Pharmaceuticals | Terminated | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00435448 | Jun 2005 → Dec 2006 | benign prostatic hyperplasia | Threshold Pharmaceuticals | Terminated | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lonidamine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00237536 ↗ |
| Known as | Doridamina | ChEMBL registry synonym — accepted as the source's own label CHEMBL1257030 ↗ |
| Known as | Lonidamina | ChEMBL registry synonym — accepted as the source's own label CHEMBL1257030 ↗ |
| Known as | NSC-741419 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1257030 ↗ |
| Known as | NSC-758419 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1257030 ↗ |
| Modality | Small molecule | — CHEMBL1257030 ↗ |